APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Oncology/Cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global AI Oncology/Cancer Early Screening Industry Growth and Trends Forecast to 2032

15 April 2026123 pages

Choose your research edition.

Industry ResearchAI Oncology/Cancer Early Screening Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Oncology/Cancer Early Screening Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal AI Oncology/Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Oncology/Cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal AI Oncology/Cancer Early Screening Market Analysis and Forecast 2026-2032180 pages · $4,950 USD

Market perspective

According to APO Research, the global AI Oncology/Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Oncology/Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the AI Oncology/Cancer Early Screening market include Tempus AI, Grail, Guardant Health, PathAI, Google(DeepMind), Philips Healthcare, IBM, Azra AI and Siemens Healthineers, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global AI Oncology/Cancer Early Screening market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The AI Oncology/Cancer Early Screening market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global AI Oncology/Cancer Early Screening market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to AI Oncology/Cancer Early Screening.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global AI Oncology/Cancer Early Screening market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

AI Oncology/Cancer Early Screening Market by Company

Tempus AI

Grail

Guardant Health

PathAI

Google(DeepMind)

Philips Healthcare

IBM

Azra AI

Siemens Healthineers

GE Healthcare

Intel

ConcertAI

NVIDIA Developer

Digital Diagnostics

Median Technologies

Alibaba Group

ByteDance

BGI Genomics

Guangzhou Kingmed Diagnostics Group Co., Ltd.

Amoy Diagnostics Co.,Ltd.

Tencent Miying

AI Oncology/Cancer Early Screening Segment by Type

Based on Medical Imaging

Based on Multi-omics Data

AI Oncology/Cancer Early Screening Segment by Application

Lung Cancer

Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)

Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)

Urinary System Tumors (Bladder Cancer)

Central Nervous System Tumors

Soft Tissue and Bone Tumors

Thyroid Cancer and Melanoma

AI Oncology/Cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Oncology/Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Oncology/Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Oncology/Cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of AI Oncology/Cancer Early Screening companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global AI Oncology/Cancer Early Screening Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global AI Oncology/Cancer Early Screening Market Size by Region (2021-2026) & (US$ Million) Table 3. Global AI Oncology/Cancer Early Screening Market Share by Region (2021-2026) Table 4. Global AI Oncology/Cancer Early Screening Market Size by Region (2027-2032) & (US$ Million) Table 5. Global AI Oncology/Cancer Early Screening Market Share by Region (2027-2032) Table 6. Global AI Oncology/Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global AI Oncology/Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 8. Global AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2026) Table 9. Global AI Oncology/Cancer Early Screening Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global AI Oncology/Cancer Early Screening Market Size Share Forecasted by Type (2027-2032) Table 11. North America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global AI Oncology/Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global AI Oncology/Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 23. Global AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2026) Table 24. Global AI Oncology/Cancer Early Screening Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global AI Oncology/Cancer Early Screening Market Size Share Forecasted by Application (2027-2032) Table 26. North America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. AI Oncology/Cancer Early Screening Industry Trends Table 37. AI Oncology/Cancer Early Screening Industry Drivers Table 38. AI Oncology/Cancer Early Screening Industry Opportunities and Challenges Table 39. AI Oncology/Cancer Early Screening Industry Restraints Table 40. Global AI Oncology/Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 41. Global AI Oncology/Cancer Early Screening Revenue Market Share by Company (2021-2026) Table 42. Global AI Oncology/Cancer Early Screening Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global AI Oncology/Cancer Early Screening Key Company Headquarters & Area Served Table 44. Global AI Oncology/Cancer Early Screening Company, Product Type & Application Table 45. Global AI Oncology/Cancer Early Screening Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global AI Oncology/Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Tempus AI Company Information Table 49. Tempus AI Business Overview Table 50. Tempus AI AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Tempus AI AI Oncology/Cancer Early Screening Product Portfolio Table 52. Tempus AI Recent Development Table 53. Grail Company Information Table 54. Grail Business Overview Table 55. Grail AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Grail AI Oncology/Cancer Early Screening Product Portfolio Table 57. Grail Recent Development Table 58. Guardant Health Company Information Table 59. Guardant Health Business Overview Table 60. Guardant Health AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Guardant Health AI Oncology/Cancer Early Screening Product Portfolio Table 62. Guardant Health Recent Development Table 63. PathAI Company Information Table 64. PathAI Business Overview Table 65. PathAI AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. PathAI AI Oncology/Cancer Early Screening Product Portfolio Table 67. PathAI Recent Development Table 68. Google(DeepMind) Company Information Table 69. Google(DeepMind) Business Overview Table 70. Google(DeepMind) AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Google(DeepMind) AI Oncology/Cancer Early Screening Product Portfolio Table 72. Google(DeepMind) Recent Development Table 73. Philips Healthcare Company Information Table 74. Philips Healthcare Business Overview Table 75. Philips Healthcare AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Philips Healthcare AI Oncology/Cancer Early Screening Product Portfolio Table 77. Philips Healthcare Recent Development Table 78. IBM Company Information Table 79. IBM Business Overview Table 80. IBM AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. IBM AI Oncology/Cancer Early Screening Product Portfolio Table 82. IBM Recent Development Table 83. Azra AI Company Information Table 84. Azra AI Business Overview Table 85. Azra AI AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Azra AI AI Oncology/Cancer Early Screening Product Portfolio Table 87. Azra AI Recent Development Table 88. Siemens Healthineers Company Information Table 89. Siemens Healthineers Business Overview Table 90. Siemens Healthineers AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Siemens Healthineers AI Oncology/Cancer Early Screening Product Portfolio Table 92. Siemens Healthineers Recent Development Table 93. GE Healthcare Company Information Table 94. GE Healthcare Business Overview Table 95. GE Healthcare AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. GE Healthcare AI Oncology/Cancer Early Screening Product Portfolio Table 97. GE Healthcare Recent Development Table 98. Intel Company Information Table 99. Intel Business Overview Table 100. Intel AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Intel AI Oncology/Cancer Early Screening Product Portfolio Table 102. Intel Recent Development Table 103. ConcertAI Company Information Table 104. ConcertAI Business Overview Table 105. ConcertAI AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. ConcertAI AI Oncology/Cancer Early Screening Product Portfolio Table 107. ConcertAI Recent Development Table 108. NVIDIA Developer Company Information Table 109. NVIDIA Developer Business Overview Table 110. NVIDIA Developer AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. NVIDIA Developer AI Oncology/Cancer Early Screening Product Portfolio Table 112. NVIDIA Developer Recent Development Table 113. Digital Diagnostics Company Information Table 114. Digital Diagnostics Business Overview Table 115. Digital Diagnostics AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Digital Diagnostics AI Oncology/Cancer Early Screening Product Portfolio Table 117. Digital Diagnostics Recent Development Table 118. Median Technologies Company Information Table 119. Median Technologies Business Overview Table 120. Median Technologies AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Median Technologies AI Oncology/Cancer Early Screening Product Portfolio Table 122. Median Technologies Recent Development Table 123. Alibaba Group Company Information Table 124. Alibaba Group Business Overview Table 125. Alibaba Group AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Alibaba Group AI Oncology/Cancer Early Screening Product Portfolio Table 127. Alibaba Group Recent Development Table 128. ByteDance Company Information Table 129. ByteDance Business Overview Table 130. ByteDance AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. ByteDance AI Oncology/Cancer Early Screening Product Portfolio Table 132. ByteDance Recent Development Table 133. BGI Genomics Company Information Table 134. BGI Genomics Business Overview Table 135. BGI Genomics AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. BGI Genomics AI Oncology/Cancer Early Screening Product Portfolio Table 137. BGI Genomics Recent Development Table 138. Guangzhou Kingmed Diagnostics Group Co., Ltd. Company Information Table 139. Guangzhou Kingmed Diagnostics Group Co., Ltd. Business Overview Table 140. Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Product Portfolio Table 142. Guangzhou Kingmed Diagnostics Group Co., Ltd. Recent Development Table 143. Amoy Diagnostics Co.,Ltd. Company Information Table 144. Amoy Diagnostics Co.,Ltd. Business Overview Table 145. Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Product Portfolio Table 147. Amoy Diagnostics Co.,Ltd. Recent Development Table 148. Tencent Miying Company Information Table 149. Tencent Miying Business Overview Table 150. Tencent Miying AI Oncology/Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Tencent Miying AI Oncology/Cancer Early Screening Product Portfolio Table 152. Tencent Miying Recent Development Table 153. North America AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 155. North America AI Oncology/Cancer Early Screening Market Share by Country (2021-2026) Table 156. North America AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America AI Oncology/Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 158. Europe AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe AI Oncology/Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe AI Oncology/Cancer Early Screening Market Share by Country (2021-2026) Table 161. Europe AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe AI Oncology/Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific AI Oncology/Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 165. Asia-Pacific AI Oncology/Cancer Early Screening Market Share by Country (2021-2026) Table 166. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Asia-Pacific AI Oncology/Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 168. Latin America AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America AI Oncology/Cancer Early Screening Market Share by Country (2021-2026) Table 171. Latin America AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America AI Oncology/Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 173. Middle East & Africa AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East & Africa AI Oncology/Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East & Africa AI Oncology/Cancer Early Screening Market Share by Country (2021-2026) Table 176. Middle East & Africa AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East & Africa AI Oncology/Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. AI Oncology/Cancer Early Screening Product Image Figure 3. Global AI Oncology/Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global AI Oncology/Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 5. Global AI Oncology/Cancer Early Screening Market Share by Region: 2025 VS 2032 Figure 6. Global AI Oncology/Cancer Early Screening Market Share by Region (2021-2032) Figure 7. North America AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Based on Medical Imaging Image Figure 13. Global Based on Medical Imaging Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Based on Multi-omics Data Image Figure 15. Global Based on Multi-omics Data Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global AI Oncology/Cancer Early Screening Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global AI Oncology/Cancer Early Screening Market Share by Type 2025 VS 2032 Figure 18. North America AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2032) Figure 19. Europe AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2032) Figure 21. Latin America AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Share by Type (2021-2032) Figure 23. Lung Cancer Image Figure 24. Global Lung Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer) Image Figure 26. Global Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer) Image Figure 28. Global Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Urinary System Tumors (Bladder Cancer) Image Figure 30. Global Urinary System Tumors (Bladder Cancer) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Central Nervous System Tumors Image Figure 32. Global Central Nervous System Tumors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Soft Tissue and Bone Tumors Image Figure 34. Global Soft Tissue and Bone Tumors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Thyroid Cancer and Melanoma Image Figure 36. Global Thyroid Cancer and Melanoma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global AI Oncology/Cancer Early Screening Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global AI Oncology/Cancer Early Screening Market Share by Application 2025 VS 2032 Figure 39. North America AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2032) Figure 40. Europe AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2032) Figure 42. Latin America AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa AI Oncology/Cancer Early Screening Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 AI Oncology/Cancer Early Screening Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America AI Oncology/Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America AI Oncology/Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America AI Oncology/Cancer Early Screening Market Share by Country (2021-2032) Figure 49. Europe AI Oncology/Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe AI Oncology/Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe AI Oncology/Cancer Early Screening Market Share by Country (2021-2032) Figure 52. Asia-Pacific AI Oncology/Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific AI Oncology/Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific AI Oncology/Cancer Early Screening Market Share by Country (2021-2032) Figure 55. Latin America AI Oncology/Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America AI Oncology/Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America AI Oncology/Cancer Early Screening Market Share by Country (2021-2032) Figure 58. Middle East & Africa AI Oncology/Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa AI Oncology/Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa AI Oncology/Cancer Early Screening Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Based on Medical Imaging
  • Based on Multi-omics Data
Applications
  • Lung Cancer
  • Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
  • Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
  • Urinary System Tumors (Bladder Cancer)
  • Central Nervous System Tumors
  • Soft Tissue and Bone Tumors
  • Thyroid Cancer and Melanoma
Companies covered
  • Tempus AI
  • Grail
  • Guardant Health
  • PathAI
  • Google(DeepMind)
  • Philips Healthcare
  • IBM
  • Azra AI
  • Siemens Healthineers
  • GE Healthcare
  • Intel
  • ConcertAI
  • NVIDIA Developer
  • Digital Diagnostics
  • Median Technologies
  • Alibaba Group
  • ByteDance
  • BGI Genomics
  • Guangzhou Kingmed Diagnostics Group Co., Ltd.
  • Amoy Diagnostics Co.,Ltd.
  • Tencent Miying

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global AI Oncology/Cancer Early Screening Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global AI Oncology/Cancer Early Screening Market Size by Region (2021-2032)
  5. 1.4.1 Global AI Oncology/Cancer Early Screening Market Size by Region (2021-2026)
  6. 1.4.2 Global AI Oncology/Cancer Early Screening Market Size by Region (2027-2032)
  7. 1.5 Key Regions AI Oncology/Cancer Early Screening Market Size (2021-2032)
  8. 1.5.1 North America AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa AI Oncology/Cancer Early Screening Market Size Growth Rate (2021-2032)
2 AI Oncology/Cancer Early Screening Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Based on Medical Imaging
  3. 2.1.2 Based on Multi-omics Data
  4. 2.2 Global AI Oncology/Cancer Early Screening Market Size by Type
  5. 2.2.1 Global AI Oncology/Cancer Early Screening Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global AI Oncology/Cancer Early Screening Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global AI Oncology/Cancer Early Screening Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global AI Oncology/Cancer Early Screening Market Size by Regions
  9. 2.3.1 North America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Type (2021-2026)
3 AI Oncology/Cancer Early Screening Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Lung Cancer
  3. 3.1.2 Digestive System Tumors (Colorectal Cancer/Pancreatic Cancer/Liver Cancer/Gastric Cancer)
  4. 3.1.3 Breast Cancer and Gynecological Tumors (Ovarian Cancer/Cervical Cancer)
  5. 3.1.4 Urinary System Tumors (Bladder Cancer)
  6. 3.1.5 Central Nervous System Tumors
  7. 3.1.6 Soft Tissue and Bone Tumors
  8. 3.1.7 Thyroid Cancer and Melanoma
  9. 3.2 Global AI Oncology/Cancer Early Screening Market Size by Application
  10. 3.2.1 Global AI Oncology/Cancer Early Screening Market Size Overview by Application (2021-2032)
  11. 3.2.2 Global AI Oncology/Cancer Early Screening Historic Market Size Review by Application (2021-2026)
  12. 3.2.3 Global AI Oncology/Cancer Early Screening Market Size Forecasted by Application (2027-2032)
  13. 3.3 Global AI Oncology/Cancer Early Screening Market Size by Regions
  14. 3.3.1 North America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  15. 3.3.2 Europe AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  16. 3.3.3 Asia-Pacific AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  17. 3.3.4 South America AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  18. 3.3.5 Middle East and Africa AI Oncology/Cancer Early Screening Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 AI Oncology/Cancer Early Screening Industry Trends
  2. 4.2 AI Oncology/Cancer Early Screening Industry Drivers
  3. 4.3 AI Oncology/Cancer Early Screening Industry Opportunities and Challenges
  4. 4.4 AI Oncology/Cancer Early Screening Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by AI Oncology/Cancer Early Screening Revenue (2021-2026)
  2. 5.2 Global AI Oncology/Cancer Early Screening Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global AI Oncology/Cancer Early Screening Key Company Headquarters & Area Served
  4. 5.4 Global AI Oncology/Cancer Early Screening Company, Product Type & Application
  5. 5.5 Global AI Oncology/Cancer Early Screening Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global AI Oncology/Cancer Early Screening Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 AI Oncology/Cancer Early Screening Players Market Share by Revenue in 2025
  9. 5.6.3 2025 AI Oncology/Cancer Early Screening Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Tempus AI
  2. 6.1.1 Tempus AI Company Information
  3. 6.1.2 Tempus AI Business Overview
  4. 6.1.3 Tempus AI AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Tempus AI AI Oncology/Cancer Early Screening Product Portfolio
  6. 6.1.5 Tempus AI Recent Developments
  7. 6.2 Grail
  8. 6.2.1 Grail Company Information
  9. 6.2.2 Grail Business Overview
  10. 6.2.3 Grail AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Grail AI Oncology/Cancer Early Screening Product Portfolio
  12. 6.2.5 Grail Recent Developments
  13. 6.3 Guardant Health
  14. 6.3.1 Guardant Health Company Information
  15. 6.3.2 Guardant Health Business Overview
  16. 6.3.3 Guardant Health AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Guardant Health AI Oncology/Cancer Early Screening Product Portfolio
  18. 6.3.5 Guardant Health Recent Developments
  19. 6.4 PathAI
  20. 6.4.1 PathAI Company Information
  21. 6.4.2 PathAI Business Overview
  22. 6.4.3 PathAI AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 PathAI AI Oncology/Cancer Early Screening Product Portfolio
  24. 6.4.5 PathAI Recent Developments
  25. 6.5 Google(DeepMind)
  26. 6.5.1 Google(DeepMind) Company Information
  27. 6.5.2 Google(DeepMind) Business Overview
  28. 6.5.3 Google(DeepMind) AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Google(DeepMind) AI Oncology/Cancer Early Screening Product Portfolio
  30. 6.5.5 Google(DeepMind) Recent Developments
  31. 6.6 Philips Healthcare
  32. 6.6.1 Philips Healthcare Company Information
  33. 6.6.2 Philips Healthcare Business Overview
  34. 6.6.3 Philips Healthcare AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Philips Healthcare AI Oncology/Cancer Early Screening Product Portfolio
  36. 6.6.5 Philips Healthcare Recent Developments
  37. 6.7 IBM
  38. 6.7.1 IBM Company Information
  39. 6.7.2 IBM Business Overview
  40. 6.7.3 IBM AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 IBM AI Oncology/Cancer Early Screening Product Portfolio
  42. 6.7.5 IBM Recent Developments
  43. 6.8 Azra AI
  44. 6.8.1 Azra AI Company Information
  45. 6.8.2 Azra AI Business Overview
  46. 6.8.3 Azra AI AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Azra AI AI Oncology/Cancer Early Screening Product Portfolio
  48. 6.8.5 Azra AI Recent Developments
  49. 6.9 Siemens Healthineers
  50. 6.9.1 Siemens Healthineers Company Information
  51. 6.9.2 Siemens Healthineers Business Overview
  52. 6.9.3 Siemens Healthineers AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Siemens Healthineers AI Oncology/Cancer Early Screening Product Portfolio
  54. 6.9.5 Siemens Healthineers Recent Developments
  55. 6.10 GE Healthcare
  56. 6.10.1 GE Healthcare Company Information
  57. 6.10.2 GE Healthcare Business Overview
  58. 6.10.3 GE Healthcare AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 GE Healthcare AI Oncology/Cancer Early Screening Product Portfolio
  60. 6.10.5 GE Healthcare Recent Developments
  61. 6.11 Intel
  62. 6.11.1 Intel Company Information
  63. 6.11.2 Intel Business Overview
  64. 6.11.3 Intel AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Intel AI Oncology/Cancer Early Screening Product Portfolio
  66. 6.11.5 Intel Recent Developments
  67. 6.12 ConcertAI
  68. 6.12.1 ConcertAI Company Information
  69. 6.12.2 ConcertAI Business Overview
  70. 6.12.3 ConcertAI AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 ConcertAI AI Oncology/Cancer Early Screening Product Portfolio
  72. 6.12.5 ConcertAI Recent Developments
  73. 6.13 NVIDIA Developer
  74. 6.13.1 NVIDIA Developer Company Information
  75. 6.13.2 NVIDIA Developer Business Overview
  76. 6.13.3 NVIDIA Developer AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 NVIDIA Developer AI Oncology/Cancer Early Screening Product Portfolio
  78. 6.13.5 NVIDIA Developer Recent Developments
  79. 6.14 Digital Diagnostics
  80. 6.14.1 Digital Diagnostics Company Information
  81. 6.14.2 Digital Diagnostics Business Overview
  82. 6.14.3 Digital Diagnostics AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Digital Diagnostics AI Oncology/Cancer Early Screening Product Portfolio
  84. 6.14.5 Digital Diagnostics Recent Developments
  85. 6.15 Median Technologies
  86. 6.15.1 Median Technologies Company Information
  87. 6.15.2 Median Technologies Business Overview
  88. 6.15.3 Median Technologies AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Median Technologies AI Oncology/Cancer Early Screening Product Portfolio
  90. 6.15.5 Median Technologies Recent Developments
  91. 6.16 Alibaba Group
  92. 6.16.1 Alibaba Group Company Information
  93. 6.16.2 Alibaba Group Business Overview
  94. 6.16.3 Alibaba Group AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Alibaba Group AI Oncology/Cancer Early Screening Product Portfolio
  96. 6.16.5 Alibaba Group Recent Developments
  97. 6.17 ByteDance
  98. 6.17.1 ByteDance Company Information
  99. 6.17.2 ByteDance Business Overview
  100. 6.17.3 ByteDance AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 ByteDance AI Oncology/Cancer Early Screening Product Portfolio
  102. 6.17.5 ByteDance Recent Developments
  103. 6.18 BGI Genomics
  104. 6.18.1 BGI Genomics Company Information
  105. 6.18.2 BGI Genomics Business Overview
  106. 6.18.3 BGI Genomics AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 BGI Genomics AI Oncology/Cancer Early Screening Product Portfolio
  108. 6.18.5 BGI Genomics Recent Developments
  109. 6.19 Guangzhou Kingmed Diagnostics Group Co., Ltd.
  110. 6.19.1 Guangzhou Kingmed Diagnostics Group Co., Ltd. Company Information
  111. 6.19.2 Guangzhou Kingmed Diagnostics Group Co., Ltd. Business Overview
  112. 6.19.3 Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Guangzhou Kingmed Diagnostics Group Co., Ltd. AI Oncology/Cancer Early Screening Product Portfolio
  114. 6.19.5 Guangzhou Kingmed Diagnostics Group Co., Ltd. Recent Developments
  115. 6.20 Amoy Diagnostics Co.,Ltd.
  116. 6.20.1 Amoy Diagnostics Co.,Ltd. Company Information
  117. 6.20.2 Amoy Diagnostics Co.,Ltd. Business Overview
  118. 6.20.3 Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Amoy Diagnostics Co.,Ltd. AI Oncology/Cancer Early Screening Product Portfolio
  120. 6.20.5 Amoy Diagnostics Co.,Ltd. Recent Developments
  121. 6.21 Tencent Miying
  122. 6.21.1 Tencent Miying Company Information
  123. 6.21.2 Tencent Miying Business Overview
  124. 6.21.3 Tencent Miying AI Oncology/Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Tencent Miying AI Oncology/Cancer Early Screening Product Portfolio
  126. 6.21.5 Tencent Miying Recent Developments
7 North America
  1. 7.1 North America AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
  3. 7.3 North America AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
  3. 8.3 Europe AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
  3. 10.3 South America AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa AI Oncology/Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa AI Oncology/Cancer Early Screening Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa AI Oncology/Cancer Early Screening Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst